source
- Revolution Medicines reports promising early data for KRAS drug combo, plans Phase 3 in pancreatic cancerRevolution Medicines presented early-stage results that support moving forward with a Phase 3 study of a combination of two KRAS-targeted agents in pancreatic cancer. The data, shown for the first…
- Sandoz launches direct-to-consumer platform with growth-hormone biosimilar OmnitropeSandoz announced a direct-to-consumer platform, initially offering Omnitrope, a biosimilar growth hormone for growth disorders. The approach follows a trend among brand-name manufacturers to lower…